Full Press Release Details
New Data From Immutep’s Efti To Be Presented At ESMO.
IMMP
New Data From Immutep’s Efti To Be Presented At ESMO
Key Takeaway: New Data From Immutep’s Efti To Be Presented At ESMO
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)